Adamis Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants
31 Julio 2019 - 3:05PM
Adamis Pharmaceuticals Corporation (Nasdaq: ADMP), a specialty
biopharmaceutical company focused on developing and commercializing
products in various therapeutic areas, including respiratory
disease, allergy and opioid overdose, announced today that it
intends to offer to sell shares of its common stock and warrants to
purchase shares of its common stock in an underwritten public
offering. The company expects to grant the underwriters of the
offering a 30-day option to purchase up to an additional 15% of the
number of shares of common stock and/or warrants to purchase shares
of its common stock offered in the public offering. The proposed
offering is subject to market and other conditions, and there can
be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering.
Raymond James & Associates, Inc. will act as the sole
book-running manager for the proposed offering.
The company intends to use the net proceeds from this offering
for general corporate purposes, which may include, without
limitation, expenditures relating to research, development and
clinical trials relating to its products and product candidates,
manufacturing, capital expenditures, hiring additional personnel,
acquisitions of new technologies or products, the payment,
repayment, refinancing, redemption or repurchase of existing or
future indebtedness, obligations or capital stock, and working
capital.
The securities described above will be offered by the company
pursuant to a “shelf” registration statement on Form S-3 (File No.
333-226100) previously filed with and declared effective by the
Securities and Exchange Commission (the “SEC”) on July 18, 2018. A
preliminary prospectus supplement and an accompanying prospectus
relating to the offering will be filed with the SEC. Electronic
copies of the preliminary prospectus supplement and the
accompanying prospectus relating to the offering may be obtained,
when available, from Raymond James & Associates, Inc.,
Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg,
Florida 33716, by telephone at (800) 248-8863, by e-mail at
prospectus@raymondjames.com, or by accessing the SEC’s website at
www.sec.gov.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities described herein,
nor shall there be any sale of these securities in any state or
other jurisdiction in which such offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Adamis Pharmaceuticals Corporation
Adamis Pharmaceuticals Corporation is a specialty
biopharmaceutical company focused on developing and commercializing
products in various therapeutic areas, including respiratory
disease, allergy and opioid overdose. The company’s
SYMJEPI™ (epinephrine) Injection 0.3mg and SYMJEPI
(epinephrine) Injection 0.15mg products are FDA approved for use in
the emergency treatment of acute allergic reactions, including
anaphylaxis. The company is developing additional products,
including the company’s ZIMHI™ naloxone injection product
candidate for the treatment of opioid overdose, and a metered dose
inhaler and dry powder inhaler product candidates for the treatment
of asthma. The company’s subsidiary, U.S. Compounding, Inc.,
compounds sterile prescription drugs and certain nonsterile drugs
for human and veterinary use, to patients, physician clinics,
hospitals, surgery centers and other clients throughout most of the
United States.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements regarding the proposed public offering
and the intended use of proceeds from the offering and statements
about the progress of development of the company’s product
candidates. The offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed or as to the actual size or terms of the offering.
These forward-looking statements also are subject to risks,
uncertainties and assumptions, including those detailed from time
to time in the company’s filings with the SEC, and represent the
company’s views only as of the date they are made and should not be
relied upon as representing the company’s views as of any
subsequent date. The company’s actual results may differ materially
from those contemplated by these forward-looking statements. Except
to the extent required by law, the company does not undertake to
update any of these forward-looking statements to reflect a change
in its views or events or circumstances that occur after the date
of this press release.
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Adamis Pharmaceuticals (NASDAQ:ADMP)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024